Dr. John Cush RheumNow
1 year 5 months ago
Neuropsychiatric Lupus: More than just a headache
Presentation by Dr. Daniel Carlson, at the Rheumatology Winter Clinical Symposia - Feb 2025
https://t.co/v0da4UNFNV https://t.co/BhBKOgak4W
Dr. Jack Cush reviews the news, journal reports and regulatory actions from the past week on RheumNow.com
Dr. John Cush RheumNow
1 year 5 months ago
Normalizing Serologies Enhances Remission in SLE
Analysis of five phase III belimumab (BEL) trials reveals that normalizing serologies affords protection against severe and renal SLE flares, supporting the concept of treat-to-target to minimize risk in SLE.… https://t.co/eW9EUyvts7 https://t.co/OdM0WkLtjd
Dr. John Cush RheumNow
1 year 5 months ago
Intraarticular Steroids in OA Lowers Need for Pain Meds
Is it possible that intra-articular corticosteroid injections for osteoarthritis might affect the use of opioids?
https://t.co/pw6vWbFRQx https://t.co/5KrB9uJv7M
Idiopathic pulmonary fibrosis (IPF), a progressive lung disease characterized by scarring and worsening lung function, has a poor prognosis. An estimated 21% of IPF deaths might be attributable to occupational exposures.
Dr. John Cush RheumNow
1 year 5 months ago
Genentech announced that FDA has accepted a Supplemental Biologics License Application for obinutuzumab (anti-CD20 mAb; Gazyva) for the Treatment of Lupus Nephritis based on positive results from Phase III REGENCY study. FDA decision by October 2025 https://t.co/Mx3YDUfkMg https://t.co/MTBZo1TCrK
A cohort analysis of ambulatory emergency department (ED) utilization by patients with psoriatic arthritis (PsA) and radiographic axial spondyloarthritis (r-axSpA) demonstrated significant use for less urgent and nonurgent health issues, particularly in rural settings.
Dr. John Cush RheumNow
1 year 5 months ago
Sleep disturbance increases disability progression - Prospective cohort data from from 70K Nurses’ Health Study w/ 392 having MS, 7,302 DM, & 25K OA. Having Sleep apnea or disturbances signif incr disability in OA & DM (OR~1.4) as was excessive daytime sleepiness… https://t.co/5PP18gqDqi https://t.co/u1HFOstv8W
Dr. John Cush RheumNow
1 year 5 months ago
FDA grants priority reviews to:
- Nicalizumab (J&J; FcRn antibody) for use in Myasthenia gravis.
- Upadacitinib (AbbVie; JAK inhib) for use in GCA
- Namistat (BI: PDE4B inhib) for use in Idiopathic pulmonary fibrosis
- Inalizumab (Hansen; anti-CD19) for use in IG4 rel Dz
-… https://t.co/dsg9vZASrk https://t.co/8t2USASmm8
A current review in the Journal of Thoracic Disease on relapsing polychondritis (RP), suggests that while this rare disorder may have an uncertain pathogenesis, its diagnosis and therapeutical management has improved.This review focuses on key features, with damage to auricular or nasal cartilage, and tracheobronchial and cardiac involvement that can be severe, and life threatening.
Dr. John Cush RheumNow
1 year 5 months ago
SOCS1 Insufficiency - a Rare Inborn Error of Immunity
Lancet Rheumatology has published a population study of the rare suppressor of cytokine signalling 1 (SOCS1) insufficiency - an inborn error of immunity affecting the negative regulation of cytokine and growth factor… https://t.co/I0muoIk5GL https://t.co/jbcuAZivci
Dr. John Cush RheumNow
1 year 5 months ago
Early Hydroxychloroquine Slows Cutaneous Lupus Progression
A prospective study of patients with limited cutaneous lupus erythematosus (CLE) shows that early introduction of hydroxychloroquine (HCQ) may prevent progression to systemic lupus erythematosus (SLE).… https://t.co/cxz4DJ6AUs https://t.co/FlgwykFnfl
Dr. John Cush RheumNow
1 year 5 months ago
Bimekizumab efficacy and safety in patients with psoriatic arthritis who had skin and nail psoriasis at baseline: Up to 2-year results from two phase 3 studies
https://t.co/RZSwrj8as8
People with Crohn’s disease and related joint inflammation linked to immune system dysfunction have distinct gut bacteria or microbiota, with the bacterium Mediterraneibacter gnavus being a potential biomarker, according to new study by Weill Cornell Medicine researchers.
